Evidence map›Paper›PMID 39264962›Full record

ArticlePloS one2024

Hit screening with multivariate robust outlier detection.

Hui Sun Leong, Tianhui Zhang, Adam Corrigan, Alessia Serrano, Ulrike Künzel, Niamh Mullooly, Ceri Wiggins, Yinhai Wang, Steven Novick

Abstract read
In one paragraph

Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hui Sun LeongData Sciences and Quantitative Biology, Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.ORCID 0000-0003-0890-6432
Tianhui ZhangData Sciences and Quantitative Biology, Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, United States of America.
Adam CorriganData Sciences and Quantitative Biology, Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.
Alessia SerranoFunctional Genomics, Discovery Biology, Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.
Ulrike KünzelFunctional Genomics, Discovery Biology, Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.
Niamh MulloolyFunctional Genomics, Discovery Biology, Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.
Ceri WigginsFunctional Genomics, Discovery Biology, Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.
Yinhai WangData Sciences and Quantitative Biology, Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.ORCID 0000-0002-3671-4932
Steven NovickData Sciences and Quantitative Biology, Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, United States of America.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hit screening, which involves the identification of compounds or targets capable of modulating disease-relevant processes, is an important step in drug discovery. Some assays, such as image-based high-content screenings, produce complex multivariate readouts. To fully exploit the richness of such data, advanced analytical methods that go beyond the conventional univariate approaches should be employed. In this work, we tackle the problem of hit identification in multivariate assays. As with univariate assays, a hit from a multivariate assay can be defined as a candidate that yields an assay value sufficiently far away in distance from the mean or central value of inactives. Viewed another way, a hit is an outlier from the distribution of inactives. A method was developed for identifying multivariate hit in high-dimensional data sets based on principal components and robust Mahalanobis distance (the multivariate analogue to the Z- or T-statistic). The proposed method, termed mROUT (multivariate robust outlier detection), demonstrates superior performance over other techniques in the literature in terms of maintaining Type I error, false discovery rate and true discovery rate in simulation studies. The performance of mROUT is also illustrated on a CRISPR knockout data set from in-house phenotypic screening programme.

Indexed as

High-Throughput Screening AssaysAlgorithmsComputer SimulationDrug DiscoveryHumansMultivariate AnalysisPrincipal Component Analysis

Identifiers

PMID39264962
PMCPMC11392271

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.